MCID: INV004
MIFTS: 38

Invasive Bladder Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Invasive Bladder Transitional Cell Carcinoma

MalaCards integrated aliases for Invasive Bladder Transitional Cell Carcinoma:

Name: Invasive Bladder Transitional Cell Carcinoma 12 15
Infiltrating Bladder Urothelial Carcinoma 74
Invasive Bladder Urothelial Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6477
NCIt 51 C27885
UMLS 74 C1334281

Summaries for Invasive Bladder Transitional Cell Carcinoma

MalaCards based summary : Invasive Bladder Transitional Cell Carcinoma, also known as infiltrating bladder urothelial carcinoma, is related to non-invasive bladder urothelial carcinoma and transitional cell carcinoma, and has symptoms including dysuria An important gene associated with Invasive Bladder Transitional Cell Carcinoma is NOTCH1 (Notch Receptor 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Cisplatin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include prostate, kidney and tongue, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Invasive Bladder Transitional Cell Carcinoma

Graphical network of the top 20 diseases related to Invasive Bladder Transitional Cell Carcinoma:



Diseases related to Invasive Bladder Transitional Cell Carcinoma

Symptoms & Phenotypes for Invasive Bladder Transitional Cell Carcinoma

UMLS symptoms related to Invasive Bladder Transitional Cell Carcinoma:


dysuria

GenomeRNAi Phenotypes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

27 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.62 CDKN1A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.62 TP53
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.62 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.62 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.62 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.62 HOXA13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.62 HOXA13
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.62 HOXA13 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.62 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.62 HOXA13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.62 HOXA13
12 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.62 CDKN1A
13 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.62 TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.62 CDKN1A HOXA13 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.62 CDKN1A
16 Increased shRNA abundance (Z-score > 2) GR00366-A-76 9.62 CDKN1A
17 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.62 CDKN1A

MGI Mouse Phenotypes related to Invasive Bladder Transitional Cell Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.46 CDKN1A HOXA13 NOTCH1 TP53
2 hearing/vestibular/ear MP:0005377 9.26 CDKN1A MSRB3 NOTCH1 TP53
3 renal/urinary system MP:0005367 8.92 CDKN1A HOXA13 NOTCH1 TP53

Drugs & Therapeutics for Invasive Bladder Transitional Cell Carcinoma

Drugs for Invasive Bladder Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Doxorubicin Approved, Investigational Phase 1, Phase 2,Phase 2 23214-92-8 31703
3
Durvalumab Approved, Investigational Phase 1, Phase 2,Phase 2 1428935-60-7
4
Vinblastine Approved Phase 1, Phase 2,Phase 2 865-21-4 241903 13342
5
Methotrexate Approved Phase 1, Phase 2,Phase 2 1959-05-2, 59-05-2 126941
6
Gemcitabine Approved Phase 2,Not Applicable 95058-81-4 60750
7
nivolumab Approved Phase 2,Phase 1 946414-94-4
8
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
9
leucovorin Approved Phase 2 58-05-9 143 6006
10
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
11
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
12
Daunorubicin Approved Phase 2 20830-81-3 30323
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
14
Doxil Approved June 1999 Phase 1, Phase 2,Phase 2 31703
15
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
16 Antibodies Phase 1, Phase 2,Phase 2
17 Immunologic Factors Phase 1, Phase 2,Phase 2,Not Applicable
18 Immunoglobulins Phase 1, Phase 2,Phase 2
19 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
20 Antineoplastic Agents, Immunological Phase 1, Phase 2,Phase 2
21 Antimetabolites Phase 2,Not Applicable
22 Anti-Infective Agents Phase 2,Not Applicable
23 Immunosuppressive Agents Phase 2,Not Applicable
24 Antiviral Agents Phase 2,Not Applicable
25 Antimetabolites, Antineoplastic Phase 2,Not Applicable
26 Folic Acid Antagonists Phase 2
27 Nucleic Acid Synthesis Inhibitors Phase 2
28 Folate Phase 2
29 Vitamin B9 Phase 2
30 Vitamin B Complex Phase 2
31 Anti-Bacterial Agents Phase 2
32 Topoisomerase Inhibitors Phase 2
33 Antibiotics, Antitubercular Phase 2
34 Antimitotic Agents Phase 2
35 Antirheumatic Agents Phase 2
36 Dermatologic Agents Phase 2
37 Antineoplastic Agents, Phytogenic Phase 2
38
Altretamine Approved Phase 1 645-05-6 2123
39 Immunoglobulin G Phase 1

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Bristol Bladder Trial Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
2 NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma Recruiting NCT03549715 Phase 1, Phase 2 Durvalumab;Tremelimumab;MVAC Protocol
3 A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer Recruiting NCT01495676 Phase 2
4 Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer Recruiting NCT03609216 Phase 2 Gemcitabine Hydrochloride;Cisplatin
5 Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
6 Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer Recruiting NCT03744793 Phase 2 Avelumab;Pemetrexed
7 Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
8 Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer Withdrawn NCT03419130 Phase 2
9 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery Recruiting NCT02812420 Phase 1
10 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib;Cabozantinib S-malate
11 sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer Recruiting NCT02767921 Phase 1
12 Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma Withdrawn NCT03430687 Phase 1
13 Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer Recruiting NCT02688348 Not Applicable
14 Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors Withdrawn NCT03238664 Not Applicable
15 Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery Withdrawn NCT02944357 Not Applicable Cisplatin;Gemcitabine Hydrochloride

Search NIH Clinical Center for Invasive Bladder Transitional Cell Carcinoma

Genetic Tests for Invasive Bladder Transitional Cell Carcinoma

Anatomical Context for Invasive Bladder Transitional Cell Carcinoma

MalaCards organs/tissues related to Invasive Bladder Transitional Cell Carcinoma:

42
Prostate, Kidney, Tongue, Skin, Brain, Spinal Cord, B Cells

Publications for Invasive Bladder Transitional Cell Carcinoma

Articles related to Invasive Bladder Transitional Cell Carcinoma:

# Title Authors Year
1
Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma. ( 24196429 )
2014
2
Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. ( 23479173 )
2013
3
Overexpression of RING box protein-1 (RBX1) associated with poor prognosis of non-muscle-invasive bladder transitional cell carcinoma. ( 23609182 )
2013
4
[Expression analysis of NOTCH1/HES1/PTEN signaling pathway in invasive bladder transitional cell carcinoma]. ( 22781569 )
2012
5
Proteomics research on muscle-invasive bladder transitional cell carcinoma. ( 21645413 )
2011
6
Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. ( 17222615 )
2007
7
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. ( 17011058 )
2006
8
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. ( 11696726 )
2001

Variations for Invasive Bladder Transitional Cell Carcinoma

Expression for Invasive Bladder Transitional Cell Carcinoma

Search GEO for disease gene expression data for Invasive Bladder Transitional Cell Carcinoma.

Pathways for Invasive Bladder Transitional Cell Carcinoma

Pathways related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1 12.48 CDKN1A NOTCH1 TP53
2
Show member pathways
12.37 CDKN1A NOTCH1 TP53
3
Show member pathways
12.31 CDKN1A NOTCH1 TP53
4 11.97 CDKN1A NOTCH1 TP53
5 11.57 CDKN1A TP53
6 11.54 CDKN1A TP53
7
Show member pathways
11.53 CDKN1A TP53
8 11.49 CDKN1A TP53
9 11.44 CDKN1A NOTCH1
10 11.42 CDKN1A TP53
11 11.41 CDKN1A TP53
12 11.33 NOTCH1 TP53
13 11.2 CDKN1A TP53
14 11.18 CDKN1A TP53
15 11.16 CDKN1A TP53
16 11.1 CDKN1A TP53
17 11.05 CDKN1A TP53
18 10.96 CDKN1A TP53
19 10.76 CDKN1A TP53
20
Show member pathways
10.5 CDKN1A TP53
21 10.03 CDKN1A TP53
22
Show member pathways
9.53 CDKN1A TP53

GO Terms for Invasive Bladder Transitional Cell Carcinoma

Biological processes related to Invasive Bladder Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.63 CDKN1A NOTCH1 TP53
2 Ras protein signal transduction GO:0007265 9.48 CDKN1A TP53
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.43 CDKN1A TP53
4 animal organ regeneration GO:0031100 9.4 CDKN1A NOTCH1
5 cellular response to ionizing radiation GO:0071479 9.37 CDKN1A TP53
6 intrinsic apoptotic signaling pathway GO:0097193 9.32 CDKN1A TP53
7 positive regulation of reactive oxygen species metabolic process GO:2000379 9.26 CDKN1A TP53
8 replicative senescence GO:0090399 9.16 CDKN1A TP53
9 cell cycle arrest GO:0007050 9.13 CDKN1A NOTCH1 TP53
10 signal transduction by p53 class mediator GO:0072331 8.62 CDKN1A TP53

Sources for Invasive Bladder Transitional Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....